Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review.
Journal
International journal of dermatology
ISSN: 1365-4632
Titre abrégé: Int J Dermatol
Pays: England
ID NLM: 0243704
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
16
09
2019
revised:
10
01
2020
accepted:
12
01
2020
pubmed:
14
2
2020
medline:
20
1
2021
entrez:
14
2
2020
Statut:
ppublish
Résumé
The use of checkpoint inhibitors for treatment of advanced malignancies is increasing. Rashes, pruritus, and more rarely, reactions resembling Stevens-Johnsons syndrome (SJS) or toxic epidermal necrolysis (TEN) may occur secondary to checkpoint inhibitors. To characterize existing literature on these reports, we queried the PubMed/MEDLINE database for cases of SJS or TEN associated with checkpoint inhibitors. We identified 18 cases of SJS or TEN-like reactions to checkpoint inhibitors in the literature. There were 12 cases of SJS-like rashes with median time to onset of 5.6 weeks (average of 8.9 weeks), of which five were delayed to week 8 or later from checkpoint inhibitor initiation. The five TEN-like reactions had a median time to onset of 4 weeks (average of 5.38 weeks), of which two were delayed to week 6 or later. SJS/TEN-like reactions to nivolumab (seven cases) had median onset time of 3 weeks, whereas five cases secondary to pembrolizumab had median onset time of 11 weeks. Seven cases in this study described prodromal rashes, which varied from localized papular rashes to generalized morbilliform rashes, prior to evolution into SJS or TEN-like patterns. SJS-like patterns generally improved well on systemic treatment/supportive care and no cases of death were identified, but mortality occurred in three of five patients with TEN-like reactions. Dermatologists should consider the possibility for unique features of SJS/TEN in response to checkpoint inhibitors. Additional studies will be necessary to further characterize SJS/TEN-like eruptions on checkpoint inhibitors and determine the optimal management of these cases.
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e183-e188Informations de copyright
© 2020 The International Society of Dermatology.
Références
Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016; 39(1): 98-106.
Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018; 378(2): 158-168.
Coleman E, Ko C, Dai F, et al. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. J Am Acad Dermatol. 2019; 80(4): 990-997.
Hua C, Boussemart L, Mateus C, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatology. 2016; 152(1): 45-51.
Lu J, Thuraisingam T, Chergui M, et al. Nivolumab-associated DRESS syndrome: a case report. JAAD Case Rep. 2019; 5(3): 216-218.
Zhao CY, Hwang SJE, Consuegra G, et al. Anti-programmed cell death-1 therapy-associated bullous disorders: a systematic review of the literature. Melanoma Res. 2018; 28(6): 491-501.
Sibaud V. Dermatologic reactions to immune checkpoint inhibitors. Am J Clin Dermatol. 2018; 19(3): 345-361.
Nayar N, Briscoe K, Fernandez PP. Toxic epidermal necrolysis-like reaction with severe satellite cell necrosis associated with nivolumab in a patient with ipilimumab refractory metastatic melanoma. J Immunother. 2016; 39(3): 149-152.
Dasanu CA. Late-onset Stevens-Johnson syndrome due to nivolumab use for hepatocellular carcinoma. J Oncol Pharm Pract. 2019; 25(8): 2052-2055.
Vivar KL, Deschaine M, Messina J, et al. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol. 2017; 44(4): 381-384.
Rouyer L, Bursztejn A-C, Charbit L, et al. Stevens-Johnson syndrome associated with radiation recall dermatitis in a patient treated with nivolumab. Eur J Dermatol. 2018; 28(3): 380-381.
Shah KM, Rancour EA, Al-Omari A, et al. Striking enhancement at the site of radiation for nivolumab-induced Stevens-Johnson syndrome. Dermatol Online J. 2018; 24(6).
Griffin LL, Cove-Smith L, Alachkar H, et al. Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma. JAAD Case Rep. 2018; 4(3): 229-231.
Salati M, Pifferi M, Baldessari C, et al. Stevens-Johnson syndrome during nivolumab treatment of NSCLC. Ann Oncol. 2017; 29(1): 283-284.
Ito J, Fujimoto D, Nakamura A, et al. Aprepitant for refractory nivolumab-induced pruritus. Lung Cancer 2017; 109: 58-61.
Saw S, Lee HY, Ng QS. Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients. Eur J Cancer. 2017; 81: 237-239.
Chirasuthat P, Chayavichitsilp P. Atezolizumab-induced Stevens-Johnson syndrome in a patient with non-small cell lung carcinoma. Case Rep Dermatol. 2018; 10(2): 198-202.
Hwang A, Iskandar A, Dasanu CA. Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy. J Oncol Pharm Pract. 2019; 25(6): 1520-1522.
Haratake N, Tagawa T, Hirai F, et al. Stevens-Johnson syndrome induced by pembrolizumab in a lung cancer patient. J Thorac Oncol. 2018; 13(11): 1798-1799.
Pathria M, Mundi JP, Trufant JW. A case of Stevens-Johnson syndrome in a patient on ipilimumab. Int J Case Reports Images. 2016; 7(5): 300-302.
Kumar R, Bhandari S. Pembrolizumab induced toxic epidermal necrolysis. Curr Probl Cancer. 2019; 100478. https://doi.org/10.1016/j.currproblcancer.2019.05.001.
Kubicki S, Welborn M, Patel A. Toxic epidermal necrolysis during cotherapy with ipilimumab and nivolumab. J Immunother Precis Oncol. 2018; 1(2): 78-81.
Goldinger SM, Stieger P, Meier B, et al. Cytotoxic Cutaneous adverse drug reactions during anti-PD-1 therapy. Clin Cancer Res. 2016; 22(16): 4023-4029.
Okiyama N, Katz SI. Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes. J Autoimmun. 2014; 53: 1-9.
Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet. 1993; 25(6): 433-443.
Centanni M, Moes DJAR, Trocóniz IF, et al. Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors. Clin Pharmacokinet. 2019; 58(7): 835-857.
Sheng J, Srivastava S, Sanghavi K, et al. Clinical pharmacology considerations for the development of immune checkpoint inhibitors. J Clin Pharmacol. 2017; 57(Suppl 10): S26-S42.
Pan R-Y, Chu M-T, Wang C-W, et al. Identification of drug-specific public TCR driving severe cutaneous adverse reactions. Nat Commun. 2019; 10(1): 3569.
Wang LL, Patel G, Chiesa-Fuxench ZC, et al. Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy. JAMA Dermatol. 2018; 154(9): 1057-1061.
Min Lee CK, Li S, Tran DC, et al. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study. J Am Acad Dermatol. 2018; 79(6): 1047-1052.
Sanlorenzo M, Vujic I, Daud A, et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 2015; 151(11): 1206-1212.